{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:35:16Z","timestamp":1787841316547,"version":"build-2784847793"},"reference-count":6,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T00:00:00Z","timestamp":1516233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">Ibritumomab Tiuxetan<\/jats:italic>\n                      (Zevalin) is an anti CD-20 murine monoclonal antibody linked to the radio-isotope 90-yttrium (90Y) by the chelator Tiuxetan. It is FDA approved for treatment of relapsed low grade or follicular B-cell Non-Hodgkin\u2019s Lymphoma (NHL) or newly diagnosed follicular NHL following an initial response to first-line chemotherapy. Patients may develop Human Anti-Murine Antibodies (HAMA), following exposure to murine antibodies. There is a concern for development of hypersensitivity reactions with Ibritumomab, especially in patients with an elevated HAMA titer. Here we describe a case of a 66 year old male with elevated HAMA titer successfully treated with Zevalin without any hypersensitivity reactions. Existing literature supports our observation that Zevalin can be safely used in most patients with elevated HAMA titers.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2017.12.004","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T13:19:51Z","timestamp":1517491191000},"page":"187-188","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Ibritumomab tiuxetan (Zevalin) and elevated serum human anti-murine antibody (HAMA)"],"prefix":"10.4103","volume":"11","author":[{"given":"Sarbajit","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adanma","family":"Ayanambakkam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Ibrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Holter","family":"Charkrabarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Khawandanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"Pt 6","key":"10.1016\/j.hemonc.2017.12.004_b0005","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/icb.1990.50","article-title":"Development of human anti-murine antibody (HAMA) response in patients","volume":"68","author":"Tjandra","year":"1990","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.hemonc.2017.12.004_b0010","doi-asserted-by":"crossref","unstructured":"Jankowitz et al. Anaphylaxis after administration of ibritumomab tiuxetan for follicular non-Hodgkin lymphoma. Clin Nucl Med 2008;33(2):94\u20136.","DOI":"10.1097\/RLU.0b013e31815ef825"},{"key":"10.1016\/j.hemonc.2017.12.004_b0015","unstructured":"Mirick et al. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Q J Nucl Med Mol Imaging 2004;48(4):251\u20137."},{"key":"10.1016\/j.hemonc.2017.12.004_b0020","doi-asserted-by":"crossref","unstructured":"Goldenberg et al. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol\/Hematol 2001;39(1\u20132).","DOI":"10.1016\/S1040-8428(01)00108-1"},{"key":"10.1016\/j.hemonc.2017.12.004_b0025","doi-asserted-by":"crossref","unstructured":"Witzig et al. Safety of ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin\u2019s lymphoma. J of Clin Oncol 2003;21(7).","DOI":"10.1200\/JCO.2003.08.043"},{"key":"10.1016\/j.hemonc.2017.12.004_b0030","unstructured":"Review of Biologics License Application for IDEC Pharmaceutical ZEVALIN\u2122 Kit (BLA# 125019)."}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387618300050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387618300050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/02275670-201811030-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:49:34Z","timestamp":1787838574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02275670-201811030-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2017.12.004","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}